1. Home
  2. FLEX vs EXAS Comparison

FLEX vs EXAS Comparison

Compare FLEX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flex Ltd.

FLEX

Flex Ltd.

HOLD

Current Price

$64.21

Market Cap

22.7B

Sector

Technology

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$103.15

Market Cap

19.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLEX
EXAS
Founded
1990
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.7B
19.6B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
FLEX
EXAS
Price
$64.21
$103.15
Analyst Decision
Strong Buy
Buy
Analyst Count
8
19
Target Price
$60.00
$84.27
AVG Volume (30 Days)
3.9M
2.4M
Earning Date
02-04-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.23
N/A
Revenue
$26,835,000,000.00
$3,082,033,000.00
Revenue This Year
$7.16
$19.40
Revenue Next Year
$6.15
$13.54
P/E Ratio
$28.67
N/A
Revenue Growth
4.89
14.47
52 Week Low
$25.11
$38.81
52 Week High
$72.22
$103.42

Technical Indicators

Market Signals
Indicator
FLEX
EXAS
Relative Strength Index (RSI) 46.61 74.02
Support Level $55.16 $102.13
Resistance Level $66.19 $102.56
Average True Range (ATR) 3.44 0.32
MACD -0.50 -0.26
Stochastic Oscillator 52.15 100.00

Price Performance

Historical Comparison
FLEX
EXAS

About FLEX Flex Ltd.

Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: